IONIS PHARMACEUTICALS INC - 8-K Filing

Ionis Pharmaceuticals reported Q2 revenue of $268M and highlighted TRYNGOLZA's early launch momentum with potential for multi-billion-dollar sales. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $IONS

Read the full article at SEC EDGAR

More Regulatory news